MediLink Therapeutics (Suzhou) Co Ltd, a China-based clinical-stage biotech company, announced on Monday that it has entered into a global clinical trial collaboration and supply agreement with US biopharmaceutical company Amgen Inc (NASDAQ:AMGN).
Under the agreement, Amgen will lead a global clinical study to assess the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA in extensive-stage small cell lung cancer (ES-SCLC). MediLink will provide the investigational drug YL201 for the combination study.
The open-label, multi-centre Phase Ib trial is aimed at assessing the safety, tolerability, pharmacokinetics and efficacy of this combination regimen in ES-SCLC patients.
Both YL201 and IMDELLTRA have shown potential in ES-SCLC.
AstraZeneca's Tagrisso Recommended for EU approval for unresectable EGFR-mutated lung cancer
IDEAYA announces IDE034 as development candidate; Secures global license from Biocytogen
ANGLE plc highlights dual CTC and ctDNA analysis in NSCLC research
Mabwell announces promising pre-clinical Data of 7MW4811 at the 15th World ADC Conference
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Harbour BioMed submits IND application for HBM9378/SKB378 in COPD treatment
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant